MedDataX Logo

A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT)

NCT00235014 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1204

Last updated 2008-07-15

No results posted yet for this study

Summary

The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.

Conditions

  • Hypertension
  • Diabetes

Interventions

DRUG

trandolapril

2 mg QD

DRUG

trandolapril/verapamil

180/2 mg QD

DRUG

placebo

1 tablet QD

DRUG

verapamil

SR 240 mg QD

Sponsors & Collaborators

  • Abbott

    lead INDUSTRY

Principal Investigators

  • Global Medical Information 1-800-633-9110 · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-03-31
Primary Completion
2006-01-31

Related Clinical Trials

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00235014 on ClinicalTrials.gov